Pancreatic Elastase at Dr. Essa Lab

Pancreatic Elastase at Dr. Essa Lab

The Pancreatic Elastase stool test is a highly specialized, non-invasive diagnostic investigation used to evaluate the exocrine function of the pancreas. The pancreas is a vital organ located in the upper abdomen, performing dual roles: endocrine (secreting hormones like insulin directly into the bloodstream) and exocrine (producing digestive enzymes that flow into the small intestine). Pancreatic elastase-1 is an enzyme synthesized exclusively by the pancreatic acinar cells. Unlike other digestive enzymes such as amylase or lipase, pancreatic elastase remains remarkably stable as it passes through the gastrointestinal tract. It does not undergo significant degradation during intestinal transit and binds to bile salts, allowing it to be concentrated and measured accurately in a random stool sample.

At Dr. Essa Lab, a premier diagnostic institution in Karachi, Pakistan, the Pancreatic Elastase test is performed using advanced Enzyme-Linked Immunosorbent Assay (ELISA) technology. This test serves as the gold standard non-invasive marker for detecting Exocrine Pancreatic Insufficiency (EPI). EPI is a clinical condition characterized by the pancreas’s inability to produce or secrete adequate amounts of digestive enzymes, leading to the malabsorption of essential nutrients, particularly fats and fat-soluble vitamins (A, D, E, and K). By measuring the concentration of elastase-1 in stool, clinicians can obtain a direct reflection of the functional capacity of the pancreatic parenchyma. This test is highly valued for its diagnostic accuracy, patient convenience, and ability to differentiate pancreatic malabsorption from other gastrointestinal disorders without the need for invasive duodenal intubation procedures.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the clinical accuracy of the Pancreatic Elastase test and to prevent pre-analytical errors. Patients are advised to follow these guidelines carefully:

• Stool Consistency: The stool sample must be solid or formed. Watery, loose, or diarrheal stool samples should not be submitted for testing. Diarrhea dilutes the concentration of the elastase enzyme in the specimen, which can lead to a falsely low result (false-positive for pancreatic insufficiency). If you have active diarrhea, consult your physician or the laboratory staff at Dr. Essa Lab before collecting the sample.
• Medication Guidelines: Patients undergoing Pancreatic Enzyme Replacement Therapy (PERT) do not generally need to discontinue their medication before this test. The monoclonal antibodies used in the ELISA assay at Dr. Essa Lab specifically target human pancreatic elastase-1 and do not cross-react with animal-derived enzymes (such as porcine or bovine pancreatin) present in PERT. However, always inform your doctor about all medications, enzymes, and supplements you are taking.
• Avoid Contamination: Do not use laxatives, mineral oil, barium, or enemas for at least 48 hours prior to sample collection, as these substances can interfere with the assay.
• Fasting: No dietary restrictions or fasting are required for this test. You may eat and drink normally prior to sample collection.

During the Procedure

The collection of the stool sample is a simple, non-invasive process that can be performed in the comfort of your home. Dr. Essa Lab provides sterile specimen containers designed specifically for this purpose. The step-by-step procedure includes:

• Obtain the Container: Collect a sterile stool specimen container with an integrated spoon/scoop from any Dr. Essa Lab collection center in Karachi or other cities.
• Sample Collection: Pass stool into a clean, dry bedpan or a plastic wrap stretched over the toilet bowl. Ensure the stool does not come into contact with toilet water, urine, or household cleaning chemicals, as contamination will compromise the test results.
• Transferring the Specimen: Use the spoon attached to the container lid to collect a small portion of the formed stool (approximately the size of a walnut, or 1 to 2 grams). Place it securely inside the sterile container.
• Securing and Labeling: Tighten the cap of the container immediately to prevent leakage. Label the container clearly with your full name, age, gender, and the date and time of collection.
• Delivery: Deliver the specimen to the nearest Dr. Essa Lab branch as soon as possible. If a delay of more than two hours is expected, store the sample in a refrigerator (between 2 to 8 degrees Celsius) and transport it to the lab in an insulated cool bag. Do not freeze the sample.

When is a Pancreatic Elastase Performed?

Chronic Pancreatitis Evaluation

Chronic pancreatitis is characterized by progressive, irreversible inflammatory damage to the pancreatic parenchyma, leading to the destruction of acinar cells and progressive fibrosis. As the functional tissue is replaced by scar tissue, the pancreas loses its ability to secrete digestive enzymes. Physicians request the Pancreatic Elastase test to assess the severity of exocrine impairment in patients with known chronic pancreatitis, helping to guide therapeutic decisions and monitor the progression of the disease over time.

Cystic Fibrosis Monitoring

Cystic fibrosis is a genetic disorder that affects the cystic fibrosis transmembrane conductance regulator (CFTR) protein, leading to the production of thick, viscous secretions in various organs. In the pancreas, these thick secretions obstruct the pancreatic ducts, preventing digestive enzymes from reaching the duodenum and causing auto-digestion and progressive damage to the organ. The Pancreatic Elastase test is routinely performed in pediatric and adult patients with cystic fibrosis to detect early-onset exocrine pancreatic insufficiency and initiate timely enzyme replacement therapy.

Unexplained Chronic Diarrhea and Steatorrhea

Patients presenting with persistent, unexplained loose stools or steatorrhea (characterized by bulky, greasy, foul-smelling stools that float and are difficult to flush) require diagnostic investigation to identify the underlying cause of malabsorption. The Pancreatic Elastase test is requested by gastroenterologists to determine whether these symptoms are due to a lack of pancreatic digestive enzymes or if they stem from primary intestinal mucosal disorders, such as celiac disease or inflammatory bowel disease.

Unexplained Weight Loss and Malabsorption

When a patient experiences significant, unintentional weight loss despite maintaining a normal or increased dietary intake, it indicates a failure of nutrient absorption or digestion. Exocrine pancreatic insufficiency prevents the breakdown of complex macronutrients, particularly lipids and proteins, leading to progressive malnutrition. Measuring fecal elastase levels allows clinicians to quickly rule in or rule out pancreatic dysfunction as the primary driver of the patient’s malabsorptive state.

Type 1 or Type 2 Diabetes Complications

There is a strong clinical association between long-standing diabetes mellitus and exocrine pancreatic dysfunction. Diabetic patients may develop pancreatic atrophy or exocrine neuropathy, leading to secondary exocrine pancreatic insufficiency. Physicians utilize the Pancreatic Elastase test in diabetic patients who present with unexplained gastrointestinal symptoms, bloating, or nutritional deficiencies to evaluate whether co-existing exocrine insufficiency is contributing to their clinical presentation.

What Does a Pancreatic Elastase Detect?

The Pancreatic Elastase test is highly sensitive and specific, providing valuable clinical insights into the functional status of the pancreas. This diagnostic investigation can detect, evaluate, or assist in ruling out the following clinical findings and conditions:

• Normal exocrine pancreatic secretory capacity (indicated by concentrations greater than 200 micrograms of elastase per gram of stool).
• Mild-to-moderate exocrine pancreatic insufficiency (indicated by concentrations between 100 and 200 micrograms per gram of stool).
• Severe exocrine pancreatic insufficiency (indicated by concentrations less than 100 micrograms per gram of stool).
• Acinar cell destruction secondary to chronic calcific pancreatitis.
• Early-stage pancreatic ductal obstruction due to benign strictures or pancreatic calculi.
• Pancreatic ductal adenocarcinoma-associated exocrine blockages, particularly in tumors located in the head of the pancreas.
• Pancreatic insufficiency associated with Cystic Fibrosis in both pediatric and adult populations.
• Shwachman-Diamond syndrome, a rare genetic disorder characterized by exocrine pancreatic dysfunction and bone marrow failure.
• Post-surgical pancreatic insufficiency following a partial pancreatectomy or a Whipple procedure (pancreaticoduodenectomy).
• Secondary exocrine pancreatic insufficiency caused by mucosal damage in untreated Celiac Disease.
• Impaired exocrine function associated with advanced age-related pancreatic atrophy.
• Pancreatic parenchymal damage resulting from long-term, chronic alcohol abuse.
• Autoimmune pancreatitis-induced exocrine dysfunction.
• Secondary pancreatic insufficiency in patients with Crohn’s disease or ulcerative colitis.
• Severe protein-energy malnutrition affecting pancreatic enzyme synthesis.
• Exocrine pancreatic insufficiency associated with long-standing Type 1 or Type 2 Diabetes Mellitus.
• Zollinger-Ellison syndrome-induced inactivation of pancreatic enzymes due to excessive gastric acid secretion.
• Impaired fat-soluble vitamin absorption (Vitamins A, D, E, and K) due to inadequate lipase secretion (correlated with low elastase levels).
• Rule out pancreatic exocrine dysfunction in patients presenting with symptoms mimicking Irritable Bowel Syndrome (IBS).
• Assessment of pancreatic functional recovery following recovery from severe acute pancreatitis.
• Congenital pancreatic enzyme deficiencies, such as isolated lipase or amylase deficiency (by demonstrating normal elastase levels).
• Sphincter of Oddi dysfunction leading to impaired flow of pancreatic secretions.
• Pancreatic tissue damage secondary to systemic conditions like hemochromatosis or amyloidosis.
• The necessity for initiating Pancreatic Enzyme Replacement Therapy (PERT) in symptomatic patients.
• Monitoring of long-term exocrine function stability in patients with chronic gastrointestinal disorders.

Turnaround Time and Report Access at Dr. Essa Lab

Dr. Essa Lab is committed to providing rapid, accurate, and reliable diagnostic reports to facilitate timely clinical decisions. The turnaround time for the Pancreatic Elastase stool test is typically 24 to 48 hours from the time the specimen is received at the main laboratory. Once the analysis is complete, the report undergoes a rigorous multi-level verification process by qualified clinical pathologists to ensure the highest standards of accuracy.

Patients can access their diagnostic reports conveniently from anywhere. Dr. Essa Lab offers an online reporting portal on their official website, where patients can view, download, and print their reports using the unique patient ID and password provided on their receipt. Additionally, reports can be accessed via the Dr. Essa Lab mobile application or received directly through WhatsApp. For those who prefer physical copies, reports can be collected from any of the numerous Dr. Essa Lab collection centers located across Karachi and other major cities in Pakistan.

Pancreatic Elastase Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Fecal Elastase-1 Concentration	> 200 µg/g of stool	100 – 200 µg/g (Mild-to-Moderate EPI); < 100 µg/g (Severe EPI)
Exocrine Pancreatic Capacity	Adequate enzyme production and secretion	Impaired digestion of dietary fats, proteins, and carbohydrates
Stool Consistency & Quality	Formed or solid stool sample	Watery or loose stool (may cause false-positive low elastase levels due to dilution)
Nutrient Absorption Indicators	Normal absorption of fats and fat-soluble vitamins	Malabsorption, steatorrhea, weight loss, and vitamin deficiencies (A, D, E, K)
Pancreatic Acinar Tissue	Intact, functional acinar cell mass	Atrophy, fibrosis, or destruction of acinar tissue due to chronic inflammation
Pancreatic Duct Patency	Unobstructed flow of pancreatic juice	Obstruction due to tumors, strictures, gallstones, or protein plugs
Genetic Marker Correlation	Normal elastase levels in infants and children	Persistently low levels indicating Cystic Fibrosis or Shwachman-Diamond syndrome
Response to Therapy (PERT)	Endogenous elastase remains low (test is unaffected by animal-derived PERT)	No change in endogenous levels; clinical improvement monitored separately

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Pancreatic Elastase?

• Experienced healthcare professionals: All tests are supervised and interpreted by highly qualified clinical pathologists and microbiologists.
• Patient-focused care: Dedicated staff members provide clear instructions and support for proper sample collection and handling.
• Quality diagnostic services: Dr. Essa Lab utilizes advanced ELISA technology and high-quality reagents to ensure precise quantitative measurements.
• Professional reporting: Reports include clear reference ranges and clinical interpretations to assist physicians in making accurate diagnoses.
• Modern diagnostic approach: The laboratory adheres to international standards of quality control and participates in external quality assurance programs.
• Comfortable environment: All collection centers are designed to provide a clean, hygienic, and welcoming experience for patients.
• Convenient location: With a vast network of branches across Karachi and other cities, patients can easily drop off samples near their homes.
• Commitment to accurate diagnosis: Dr. Essa Lab has been a trusted name in diagnostics since 1987, maintaining a legacy of reliability and clinical excellence.